Page 19 - GPD-3-1

Gene & Protein in Disease Enhancing fertility with CRISPR

Ethics approval and consent to participate doi: 10.1016/j.canlet.2019.01.017

Not applicable. 10. Barrera-Paez JD, Moraes CT. Mitochondrial genome
engineering coming-of-age. Trends Genet. 2022;38(8):869-880.
Consent for publication doi: 10.1016/j.tig.2022.04.011

Not applicable. 11. Liang P, Xu Y, Zhang X, et al. CRISPR/Cas9-mediated
gene editing in human tripronuclear zygotes. Protein Cell.
Availability of data 2015;6(5):363-372.

Not applicable. doi: 10.1007/s13238-015-0153-5
References 12. Kingwell K. First CRISPR therapy seeks landmark approval.
Nat Rev Drug Discov. 2023;22:339-341.
1. Soh YQS, Alföldi J, Pyntikova T, et al. Sequencing the doi: 10.1038/d41573-023-00050-8
mouse Y chromosome reveals convergent gene acquisition
and amplification on both sex chromosomes. Cell. 13. Wong C. UK first to approve CRISPR treatment for diseases:
2014;159(4):800-813. What you need to know. Nature. 2023;623:676-677.
doi: 10.1016/j.cell.2014.09.052 doi: 10.1038/d41586-023-03590-6
2. Martin JJ, Woods DC, Tilly JL. Implications and current 14. Mercuri ND, Cox BJ. The need for more research into
limitations of oogenesis from female germline or oogonial reproductive health and disease. Elife. 2022;11:e75061.
stem cells in adult mammalian ovaries. Cells. 2019;8(2):93. doi: 10.7554/eLife.75061
doi: 10.3390/cells8020093 15. Dunleavy JEM, Dinh DT, Filby CE, et al. Reproductive
3. Bulaklak K, Gersbach CA. The once and future gene therapy. biology research down under: Highlights from the
Nat Commun. 2020;11(1):5820. Australian and New Zealand annual meeting of the
society for reproductive biology, 2021. Reprod Fertil Dev.
doi: 10.1038/s41467-020-19505-2 2022;34(13):855-866.
4. Manghwar H, Lindsey K, Zhang X, Jin S. CRISPR/Cas doi: 10.1071/rd22115
system: Recent advances and future prospects for genome
editing. Trends Plant Sci. 2019;24(12):1102-1125. 16. Zhou Q. Progress in modern reproductive biology research
in China. Biol Reprod. 2022;107(1):3-11.
doi: 10.1016/j.tplants.2019.09.006
doi: 10.1093/biolre/ioac122
5. Gupta D, Bhattacharjee O, Mandal D, et al. CRISPR-Cas9
system: A new-fangled dawn in gene editing. Life Sci. 17. Shivram H, Cress BF, Knott GJ, Doudna JA. Controlling and
2019;232:116636. enhancing CRISPR systems. Nat Chem Biol. 2021;17(1):10-19.
doi: 10.1016/j.lfs.2019.116636 doi: 10.1038/s41589-020-00700-7
6. Ishino Y, Shinagawa H, Makino K, Amemura M, 18. Katti A, Diaz BJ, Caragine CM, Sanjana NE, Dow LE.
Nakata A. Nucleotide sequence of the iap gene, responsible CRISPR in cancer biology and therapy. Nat Rev Cancer.
for alkaline phosphatase isozyme conversion in Escherichia 2022;22(5):259-279.
coli, and identification of the gene product. J Bacteriol. doi: 10.1038/s41568-022-00441-w
1987;169(12):5429-5433.
19. Gostimskaya I. CRISPR-Cas9: A history of its discovery
doi: 10.1128/jb.169.12.5429-5433.1987 and ethical considerations of its use in genome editing.
7. Ishino Y, Krupovic M, Forterre P. History of CRISPR-Cas from Biochemistry (Mosc). 2022;87(8):777-788.
Encounter with a mysterious repeated sequence to genome doi: 10.1134/s0006297922080090
editing technology. J Bacteriol. 2018;200(7):e00580-17.
20. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA,
doi: 10.1128/JB.00580-17 Charpentier E. A programmable dual-RNA–guided DNA
8. Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR- endonuclease in adaptive bacterial immunity. Science.
Cas9 Gene editing for sickle cell disease and β-thalassemia. 2012;337(6096):816-821.
N Engl J Med. 2021;384(3):252-260. doi: 10.1126/science.1225829
doi: 10.1056/NEJMoa2031054 21. Bhushan K, Chattopadhyay A, Pratap D. The evolution of
CRISPR/Cas9 and their cousins: Hope or hype? Biotechnol
9. Chen M, Mao A, Xu M, Weng Q, Mao J, Ji J. CRISPR-Cas9
for cancer therapy: Opportunities and challenges. Cancer Lett. 2018;40(3):465-477.
Lett. 2019;447:48-55. doi: 10.1007/s10529-018-2506-7

Volume 3 Issue 1 (2024) 11 https://doi.org/10.36922/gpd.2701